ICGT ICG Enterprise Trust

ICG Enterprise Trust Plc: Revolving Credit Facility Update

ICG Enterprise Trust Plc: Revolving Credit Facility Update

New €200m revolving credit facility

ICG Enterprise Trust (“ICGT”) is pleased to announce that it has entered into a new four year €200m Revolving Credit Facility (“RCF”) with Credit Suisse, effective from 26 February 2021. This replaces the previous €176m facility.

The RCF will be used to finance short term fluctuations in working capital and draw downs on commitments.

Oliver Gardey, Head of Private Equity Fund Investments at ICG, commented:

“We are very pleased to have entered into this facility, which reinforces our strong balance sheet and liquidity profile. We have an attractive pipeline of investment opportunities and are well positioned to execute them. ICG Enterprise Trust benefited from a deep pool of ICG plc expertise during the negotiation of this facility, further demonstrating the advantages of being part of the platform.”

Enquiries

Analyst / Investor enquiries:                                                                                              +44 (0) 20 3545 2000

Oliver Gardey, Head of Private Equity Fund Investments, ICG    

Colm Walsh, Managing Director, ICG                                         

James Caddy, Investor Relations, ICG                                                               

Media:

Fiona Laffan, Global Head of Corporate Affairs, ICG                                                        +44 (0) 20 3545 1510

Ed Gascoigne Pees, Eddie Livingstone-Learmonth, Camarco                                          +44 (0) 20 3757 4993

 

Disclaimer

This report may contain forward looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this report and should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying such forward-looking information. These written materials are not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption therefrom. The issuer has not and does not intend to register any securities under the US Securities Act of 1933, as amended, and does not intend to offer any securities to the public in the United States. No money, securities or other consideration from any person inside the United States is being solicited and, if sent in response to the information contained in these written materials, will not be accepted.



EN
01/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ICG Enterprise Trust

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding ICG Enterprise Trust plc (the “Company”) 2 April 2026 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them The Company received notification on 1 April 2026 that Jane Tufnell, Chair, transferred 13,283 ordinary shares in the Company ("Shares") from a General Investment Account (“GIA”) to an Individual Savings Account (“ISA”), and that she transferred 6,380 Shares to a person closely associated (“PCA”) with her, who subsequently transferred those 6,380 Shares from a GIA to ...

Mark Thomas ... (+3)
  • Mark Thomas
  • Martin Hall
  • Mike Foster

Hardman & Co Monthly: April 2026

Feature article: 2025 pharma statistics, by Dr Martin Hall, Head of Life Sciences at Hardman & Co Our pharmaceutical dataset has been compiled over 40 years from 109 companies, which, through M&A activity and consolidation, now comprise 46 companies. An efficient reporting system has seen all the listed multinational pharma companies announce results for 2025, giving us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmac...

 PRESS RELEASE

Voting Rights and Capital

Voting Rights and Capital ICG Enterprise Trust plc (the “Company”) 1 April 2026 Total Voting Rights In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company announces as follows. At the close of business on 31 March 2026, the Company had 63,554,192 Ordinary shares in issue, of which 2,074,106 were held in Treasury. Therefore, the total number of voting rights in the Company is 61,480,086.The above figure 61,480,086 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their intere...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 31 March 2026 Transaction in Own Shares The Company announces that on 30 March 2026 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1330 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 2,089,106Total shares in issue excluding treasury shares following settlement of this purchase: 61,465,086 The Company has bought back these shares under the authority granted by shareholders at i...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 25 March 2026 Transaction in Own Shares The Company announces that on 24 March 2026 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1327 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 2,074,106Total shares in issue excluding treasury shares following settlement of this purchase: 61,480,086 The Company has bought back these shares under the authority granted by shareholders at its Annual Ge...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch